Stock Price Quote

ALKEM LABORATORIES LTD.

NSE : ALKEMBSE : 539523ISIN CODE : INE540L01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE5089.50-20.7 (-0.41 %)
PREV CLOSE ( ) 5110.20
OPEN PRICE ( ) 5120.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1897
TODAY'S LOW / HIGH ( )5052.05 5123.10
52 WK LOW / HIGH ( )5052.05 5933
NSE5087.50-50.5 (-0.98 %)
PREV CLOSE( ) 5138.00
OPEN PRICE ( ) 5122.00
BID PRICE (QTY) 5087.50 (34)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 238760
TODAY'S LOW / HIGH( ) 5051.00 5128.00
52 WK LOW / HIGH ( )5051 5933.5
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 08-08 1973
Management Info
Basudeo N Singh - Chairman Sandeep Singh - Managing Director
Registered Office

Address Alkem House,Senapati Bapat Marg,Lower Parel (West),
Mumbai,
Maharashtra-400013

Phone 022 3982 9999

Email investors@alkem.com / contact@alkem.com

Website www.alkemlabs.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

08Sep Alkem Laboratories launches Ginsenosid
Alkem Laboratories has launched Renocia Exo, a next-generation hair rege..
16Jul Alkem Laboratories informs about acqui
Alkem Laboratories has informed that the Company has acquired 79,36,50,7..
02Jul Alkem Laboratories informs about news
Pursuant to Regulation 30 and 47 read alongwith Schedule III of the SEBI..
29Jun Alkem Laboratories informs about upda
In continuation of its earlier intimations dated 13th February, 2026 and..
10Jun Alkem Laboratories submit analyst meet
With reference to relevant provisions of the SEBI (Listing Obligations a..

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit5699.822820.9
Gross Profit 7984.2 25226.2
Operating Profit 8731.629795.6
Net Sales 26677.396639.1

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  25586.10 (1.24%)
M.Cap ( in Cr)54368.68
Kwality Pharma (BSE)
peergroup  3642.50 (3.65%)
M.Cap ( in Cr)3779.53
Concord Biotech (BSE)
peergroup  1506.65 (3.72%)
M.Cap ( in Cr)15762.00
Rubicon Research (BSE)
peergroup  1838.35 (2.67%)
M.Cap ( in Cr)30430.56
Onesource Specialty (BSE)
peergroup  1592.40 (3.04%)
M.Cap ( in Cr)18260.51

Shareholding Pattern

PROMOTERS 49.7%
FI/BANKS/INSURANCE 4.17%
NON-INSTITUTION 17.25%
MUTUAL FUNDS/UTI 16.71%
GOVERNMENT 0%
FII 0%

About Alkem Laboratories Ltd.

Alkem Laboratories Ltd. was incorporated in the year 1973. Its today's share price is 5089.5. Its current market capitalisation stands at Rs 60852.61 Cr. In the latest quarter, company has reported Gross Sales of Rs. 98795 Cr and Total Income of Rs.102291.8 Cr. The company's management includes Manish Narang, Diwakar Gupta, Neela Bhattacherjee, Ranjal Laxmana Shenoy, Rajeev Kher, Sujjain Talwar, Narendra Kumar Aneja, Srinivas Singh, Sarvesh Singh, Madhurima Singh, Mritunjay Kumar Singh, Sandeep Singh, Basudeo N Singh.

It is listed on the BSE with a BSE Code of 539523 , NSE with an NSE Symbol of ALKEM and ISIN of INE540L01014. It's Registered office is at Alkem House,Senapati Bapat Marg,Lower Parel (West)Mumbai-400013, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, Deloitte Haskins & Sells LLP, RS Sanghai & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.